FDA grants Breakthrough Therapy designation for Zealand Pharma’s survodutide
The FDA has granted Breakthrough Therapy designation to Zealand Pharma’s survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist...
top of page
Browse by category
Search
Browse by tag
bottom of page